CSPC Pharmaceutical Group Ltd. logo

CSPC Pharmaceutical Group Ltd. (CHJTF)

Market Closed
10 Aug, 20:00
OTC PINK OTC PINK
$
1. 07
0
0%
$
11.98B Market Cap
11.41 P/E Ratio
0.23% Div Yield
5,000 Volume
0 Eps
$ 1.07
Previous Close
Add Transaction
Day Range
1.07 1.07
Year Range
0.94 1.39
Want to track CHJTF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CHJTF closed today higher at $1.07, an increase of 0% from yesterday's close, completing a monthly increase of 9.1837% or $0.09. Over the past 12 months, CHJTF stock gained 12.6316%.
CHJTF pays dividends to its shareholders, with the most recent payment made on Jul 15, 2026. The next estimated payment will be in In 5 months on Jan 15, 2027 for a total of $0.019.
The last earnings report, released on Mar 25, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0933%, based on the last three reports.
CSPC Pharmaceutical Group Ltd. has completed 1 stock splits, with the recent split occurring on Jun 18, 2020.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

CHJTF Chart

People also search for

Fresenius SE & Co. KGaA Sponsored ADR
$ 13.57
0%
CSL Limited Sponsored ADR
$ 23.72
+0.8503%
Chugai Pharmaceutical Co. Ltd.
$ 22.24
+2.6777%
Bayer AG Sponsored ADR
$ 14.2
-1.662%
Otsuka Holdings Co., Ltd.
$ 39.48
-2.4944%

CSPC Pharmaceutical Group Ltd. (CHJTF) FAQ

What is the stock price today?

The current price is $1.07.

On which exchange is it traded?

CSPC Pharmaceutical Group Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is CHJTF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.23%.

What is its market cap?

As of today, the market cap is 11.98B.

Has CSPC Pharmaceutical Group Ltd. ever had a stock split?

CSPC Pharmaceutical Group Ltd. had 1 splits and the recent split was on Jun 18, 2020.

CSPC Pharmaceutical Group Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Lei Cai CEO
OTC PINK Exchange
HK1093012172 ISIN
CN Country
19,700 Employees
24 Jun 2026 Last Dividend
15 Oct 2020 Last Split
- IPO Date

Overview

CSPC Pharmaceutical Group Limited, established in 1992 and headquartered in Shijiazhuang, the People's Republic of China, is a prominent investment holding company specializing in the pharmaceutical sector. The company stands out for its comprehensive involvement in researching, developing, manufacturing, and distributing pharmaceutical products across a wide geographical stretch that includes the People's Republic of China, other Asian regions, North America, Europe, and beyond in the global market. Operating through its strategic divisions—Finished Drugs, Bulk Products, and Functional Food and Others—CSPC Pharmaceutical has cemented its reputation as a leading provider of a variety of pharmaceutical solutions. A significant milestone in the company's history is its strategic partnership with Pfizer Inc., aimed at launching a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, showcasing its commitment to contributing to global health crises solutions. Originally known as China Pharmaceutical Group Limited, the company rebranded to CSPC Pharmaceutical Group Limited in March 2013 to better reflect its expansive scope and ambitions.

Products and Services

  • NBP soft capsules and injections: Designed for the treatment of acute ischemic stroke, offering crucial intervention in the early stages of stroke management.
  • Oulaining capsules and injections: Prescribed for mild to moderate memory and mental impairment, enhancing cognitive functions in affected individuals.
  • Enxi: A medication aimed at treating adult idiopathic Parkinson's disease, offering relief and improving the quality of life for patients.
  • Duomeisu: Focused on the treatment of lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors, showcasing the company's dedication to cancer care.
  • Jinyouli: Developed to prevent leucopenia and infection induced by chemotherapy, supporting patients through their cancer treatment process.
  • Keaili: Another of the company’s oncology offerings, specifically targeting breast cancer treatment.
  • Antibiotics, Vitamin C, and Caffeine APIs: Critical components in the development of a range of pharmaceutical applications, highlighting CSPC's diverse approach to health solutions.
  • Functional food and glucose products: Expanding beyond pharmaceuticals, these offerings cater to the broader health and wellness sector, providing nutritional and health maintenance options.
  • Healthcare services: Beyond products, CSPC offers a spectrum of healthcare services, reinforcing its comprehensive approach towards healthcare provision and patient support.

Contact Information

Address: No.896 Zhongshandong Street
Phone: 86 31 1870 37015